poisar

Stocks · News reference

Nektar Therapeutics Announces That Jury Found Lilly Did Breach Implied Covenant Of Good Faith And Fair Dealing Under License Agreement; Company Awarded $90M In Damages Plus Interest

Benzinga Newsdesk

On September 24, 2026, the jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agreement. The jury awarded the Company $90 million in damages plus

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LLYNKTR
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Adria Cimino

    Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

    Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.

    VKTXLLYNVO